<?xml version="1.0" encoding="UTF-8"?><experiments api-version="3" api-revision="091015" version="3.0" revision="091015" total="2" total-samples="28" total-assays="28"><experiment><id>526001</id><accession>E-GEOD-23952</accession><secondaryaccession>GSE23952</secondaryaccession><name>Expression data from TGF-beta treated Panc-1 pancreatic adenocarcinoma cell line</name><releasedate>2010-09-03</releasedate><lastupdatedate>2015-08-10</lastupdatedate><organism>Homo sapiens</organism><experimenttype>transcription profiling by array</experimenttype><description><id/><text>TGF-beta treatment of Panc-1 pancreatic adenocarcinoma cell line on Affymetrix HG_U133_plus_2 arrays; triplicate experiments. The goal of the experiment is to profile temporal gene expression changes during TGF-beta-induced epithelial-mesenchymal transition (EMT). During EMT cancer cells lose their epithelial specifc proteins and gain mesenchymal proteins to acquire migratory and invasive phenotype essential for metastasis. Human Panc-1 pancreatic adenocarcinoma cell line was treated with 5 ng/mL TGF-beta for 48 h to induce EMT. The experiment was repeated 3 times. Samples were assayed using Affymetrix HG_U133_plus_2 arrays with 54675 probe-sets, using standard techniques. Human Panc-1 pancreatic adenocarcinoma cell line was treated with 5 ng/mL TGF-beta for 48 h. The experiment was repeated 3 times. Samples were assayed using Affymetrix HG_U133_plus_2 arrays with 54675 probe-sets, using standard techniques.</text></description><provider><contact>Barbara Mirel</contact><role/><email/></provider><provider><contact>HV Jagadish</contact><role/><email/></provider><provider><contact>Venkateshwar G Keshamouni</contact><role/><email/></provider><provider><contact>Gilbert S Omenn</contact><role/><email/></provider><provider><contact>brian haab</contact><role>submitter</role><email>brian.haab@vai.org</email></provider><provider><contact>James Cavalcoli</contact><role/><email/></provider><provider><contact>Rork Kuick</contact><role/><email/></provider><provider><contact>Alla Karnovsky</contact><role/><email/></provider><provider><contact>Terry Weymouth</contact><role/><email/></provider><provider><contact>Zachary Wright</contact><role/><email/></provider><provider><contact>Maureen A Sartor</contact><role/><email/></provider><provider><contact>Brian Athey</contact><role/><email/></provider><provider><contact>Vasudeva Mahavisno</contact><role/><email/></provider><bibliography><accession>20885998</accession><authors>Maupin KA, Sinha A, Eugster E, Miller J, Ross J, Paulino V, Keshamouni VG, Tran N, Berens M, Webb C, Haab BB</authors><title>Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems.</title><doi>10.1371/journal.pone.0013002</doi><status>published</status></bibliography><samplecharacteristic><category>cell line</category><value>Panc1</value></samplecharacteristic><samplecharacteristic><category>organism</category><value>Homo sapiens</value></samplecharacteristic><samplecharacteristic><category>organism part</category><value>pancreas</value></samplecharacteristic><samplecharacteristic><category>treatment</category><value>TGF-beta treated 48 hr</value><value>untreated control</value></samplecharacteristic><experimentalvariable><name>treatment</name><value>TGF-beta treated 48 hr</value><value>untreated</value></experimentalvariable><arraydesign><id>11119</id><accession>A-AFFY-44</accession><name>Affymetrix GeneChip Human Genome U133 Plus 2.0 [HG-U133_Plus_2]</name><count>6</count><legacy_id>405156763</legacy_id></arraydesign><protocol><id>1145364</id><accession>P-GSE23952-4</accession></protocol><protocol><id>1145362</id><accession>P-GSE23952-3</accession></protocol><protocol><id>1145360</id><accession>P-GSE23952-6</accession></protocol><protocol><id>1145361</id><accession>P-GSE23952-5</accession></protocol><protocol><id>1145358</id><accession>P-GSE23952-8</accession></protocol><protocol><id>1145359</id><accession>P-GSE23952-7</accession></protocol><protocol><id>1145357</id><accession>P-GSE23952-1</accession></protocol><protocol><id>1145363</id><accession>P-GSE23952-2</accession></protocol><bioassaydatagroup><id/><name>rawData</name><bioassaydatacubes>6</bioassaydatacubes><arraydesignprovider/><dataformat>rawData</dataformat><bioassays>6</bioassays><isderived>0</isderived></bioassaydatagroup><bioassaydatagroup><id/><name>normalization</name><bioassaydatacubes>6</bioassaydatacubes><arraydesignprovider/><dataformat>normalization</dataformat><bioassays>6</bioassays><isderived>0</isderived></bioassaydatagroup><bioassaydatagroup><id/><name>processedData</name><bioassaydatacubes>6</bioassaydatacubes><arraydesignprovider/><dataformat>processedData</dataformat><bioassays>6</bioassays><isderived>0</isderived></bioassaydatagroup></experiment><experiment><id>200376</id><accession>E-GEOD-21654</accession><secondaryaccession>GSE21654</secondaryaccession><name>Transcription profiling by array of human pancreatic cancer cell lines</name><releasedate>2010-05-27</releasedate><lastupdatedate>2014-05-01</lastupdatedate><organism>Homo sapiens</organism><experimenttype>transcription profiling by array</experimenttype><description><id/><text>We used microarrays to analyze the global expression patterns for 22 commercially available pancreatic cancer cell lines 22 pancreatic cancer cell lines were grown to 80% confluence in DMEM/FBS/PenStrep media and then harvested for total RNA</text></description><provider><contact>Kevin A Maupin</contact><role/><email/></provider><provider><contact>Craig Webb</contact><role/><email/></provider><provider><contact>brian haab</contact><role>submitter</role><email>brian.haab@vai.org</email></provider><provider><contact>Emily Euger</contact><role/><email/></provider><provider><contact>Jeremy Miller</contact><role/><email/></provider><bibliography><accession>20885998</accession><authors>Maupin KA, Sinha A, Eugster E, Miller J, Ross J, Paulino V, Keshamouni VG, Tran N, Berens M, Webb C, Haab BB</authors><title>Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems.</title><doi>10.1371/journal.pone.0013002</doi><status>published</status></bibliography><samplecharacteristic><category>cell line</category><value>ASPC-1</value><value>BxPC-3</value><value>CaPan-2</value><value>CFPAC</value><value>Colo 357</value><value>HPAF-II</value><value>HS766t</value><value>L3.6 pl</value><value>MiaPaCa-2</value><value>Mpanc-96</value><value>Nor-P1</value><value>Panc 10.05</value><value>Panc 2.03</value><value>Panc 2.13</value><value>Panc 3.27</value><value>Panc 3.3</value><value>Panc 5.04</value><value>Panc 6.03</value><value>Panc 8.13</value><value>Panc-1</value><value>PL45</value><value>SU86.86</value></samplecharacteristic><samplecharacteristic><category>disease state</category><value>pancreatic cancer</value></samplecharacteristic><samplecharacteristic><category>Organism</category><value>Homo sapiens</value></samplecharacteristic><samplecharacteristic><category>organism part</category><value>pancreas</value></samplecharacteristic><experimentalvariable><name>cell line</name><value>ASPC-1</value><value>BxPC-3</value><value>CaPan-2</value><value>CFPAC</value><value>Colo 357</value><value>HPAF-II</value><value>HS766t</value><value>L3.6 pl</value><value>MiaPaCa-2</value><value>Mpanc-96</value><value>Nor-P1</value><value>Panc 10.05</value><value>Panc 2.03</value><value>Panc 2.13</value><value>Panc 3.27</value><value>Panc 3.3</value><value>Panc 5.04</value><value>Panc 6.03</value><value>Panc 8.13</value><value>Panc-1</value><value>PL45</value><value>SU86.86</value></experimentalvariable><arraydesign><id>11119</id><accession>A-AFFY-44</accession><name>Affymetrix GeneChip Human Genome U133 Plus 2.0 [HG-U133_Plus_2]</name><count>22</count><legacy_id>405156763</legacy_id></arraydesign><protocol><id>530798</id><accession>P-GSE21654-3</accession></protocol><protocol><id>530793</id><accession>P-GSE21654-1</accession></protocol><protocol><id>530796</id><accession>P-GSE21654-2</accession></protocol><protocol><id>530797</id><accession>P-GSE21654-5</accession></protocol><protocol><id>530799</id><accession>P-GSE21654-4</accession></protocol><protocol><id>530794</id><accession>P-GSE21654-7</accession></protocol><protocol><id>530795</id><accession>P-GSE21654-6</accession></protocol><bioassaydatagroup><id/><name>rawData</name><bioassaydatacubes>22</bioassaydatacubes><arraydesignprovider/><dataformat>rawData</dataformat><bioassays>22</bioassays><isderived>0</isderived></bioassaydatagroup><bioassaydatagroup><id/><name>scan</name><bioassaydatacubes>22</bioassaydatacubes><arraydesignprovider/><dataformat>scan</dataformat><bioassays>22</bioassays><isderived>0</isderived></bioassaydatagroup><bioassaydatagroup><id/><name>processedDataMatrix</name><bioassaydatacubes>1</bioassaydatacubes><arraydesignprovider/><dataformat>processedDataMatrix</dataformat><bioassays>1</bioassays><isderived>1</isderived></bioassaydatagroup></experiment></experiments>